EdgePoint Investment Group Inc. Acquires Shares of Common Stock of Novelion Therapeutics Inc.

TORONTO, July 12, 2018 /CNW/ - EdgePoint Investment Group Inc. together with EdgePoint Canadian Portfolio, EdgePoint Canadian Growth & Income Portfolio and EdgePoint Global Growth & Income Portfolio, as joint actors (collectively, the "Offeror"), announces that on November 7, 2017, it owned 1,708,062 shares of Common Stock of Novelion Therapeutics Inc. (the "Reporting Issuer") and an additional 257,263 shares of Common Stock of the Reporting Issuer issuable upon conversion of a 2.00% Convertible Senior Notes due 2019 (the "Convertible Notes"), representing 10.54% of the then issued and outstanding shares of Common Stock, assuming no other Convertible Notes had been exercised. The securities were acquired through the facilities of the Nasdaq Stock Exchange and the consideration paid per security was CAD$6.02 (USD $4.71). 

As at June 30, 2018, the Offeror exercises control over 2,195,063 shares of Common Stock of the Reporting Issuer equivalent to approximately 11.74%, assuming approximately 18,704,857 total issued and outstanding shares of Common Stock of the Reporting Issuer.  The Offeror also exercises control over 260,999 shares of Common Stock of the Reporting Issuer issuable upon conversion of the Convertible Notes. Assuming the conversion of the Convertible Notes held by the Offeror, the Offeror would exercise control over, in aggregate, on fully diluted basis 2,456,062 (or 12.95%) shares of the Common Stock, assuming that no other Convertible Notes have been exercised.

The acquisition of the shares of Common Stock of the Reporting Issuer has been made in the ordinary course of business and was made for investment purposes. The Offeror may in the future acquire additional securities of the Reporting Issuer or may sell all or some portion of the shares of Common Stock of the Reporting Issuer it controls, or may enter into derivative or other transactions with respect to such shares of Common Stock.

The Offeror is located at 150 Bloor Street West, Suite 500, Toronto, Ontario, M5S 2X9.  The Reporting Issuer's head office is located at c/o Norton Rose Fulbright Canada LLP, 1800 – 510 West Georgia Street, Vancouver, British Columbia, V6B 0M3.

SOURCE EdgePoint Investment Group Inc.